Table II.
Effect of eculizumab on haemolysis in patients with paroxysmal nocturnal haemoglobinuria by pretreatment transfusion strata.
| TRIUMPH |
SHEPHERD |
|||||||
|---|---|---|---|---|---|---|---|---|
| Median (mean ± SE) |
Median (mean ± SE) |
|||||||
| Pretreatment transfusion strata | Baseline |
Week 26 |
Baseline |
Week 52 |
||||
| Placebo | Eculizumab | Placebo | Eculizumab | P-value* | Pretreatment | Eculizumab | P-value† | |
| Overall | 2235 (2258 ± 155) | 2032 (2200 ± 158) | 2167 (2419 ± 140) | 239 (327 ± 68) | <0·001 | 2051 (2201 ± 105) | 269 (297 ± 21) | <0·001 |
| <4 units | – | – | – | – | – | 2030 (2218 ± 211) | 264 (352 ± 89) | <0·001 |
| 4–14 units | 1642 (2001 ± 212) | 1703 (2353 ± 345) | 2060 (2297 ± 226) | 227 (424 ± 198) | <0·001 | 1876 (2124 ± 144) | 270 (284 ± 14) | <0·001 |
| 15–25 units | 2193 (2312 ± 232) | 1877 (1856 ± 162) | 2111 (2385 ± 231) | 264 (280 ± 22) | <0·001 | 2758 (2492 ± 304) | 286 (285 ± 17) | <0·001 |
| >25 units | 2414 (2519 ± 402) | 2482 (2523 ± 290) | 2805 (2640 ± 293) | 259 (273 ± 25) | <0·001 | 2123 (2119 ± 312) | 219 (262 ± 30) | <0·001 |
Values shown are lactate dehydrogenase levels (units/l). P-values are based on a comparison of the median values.
*
Wilcoxon’s rank sum test.
†
Signed rank test.